By Connor Hart
Regeneron Pharmaceuticals said it is working to determine a path forward for its treatment of several retinal conditions after the Food and Drug Administration said it didn't agree with the company's proposal to extend the interval between doses.
The FDA told Regeneron in a complete response letter that while it didn't identify any issues with the safety or efficacy of the drug in its approved indications and dosing regimens, the agency didn't agree with Regeneron's proposal to add additional extended dosing intervals
The company previously submitted a supplemental biologics license application for the addition of extended dosing intervals of up to 24 weeks for the drug, across all its approved applications.
The Tarrytown, N.Y., biotech company said Friday its treatment, Eylea HD, is approved with dosing intervals from every eight to 16 weeks for patients with wet age-related macular degeneration and diabetic macular edema, and every eight to 12 weeks for patients with diabetic retinopathy. These dosing intervals follow three initial monthly doses.
Regeneron said it is evaluating the FDA's decision and will determine a path forward in due course.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 18, 2025 15:37 ET (19:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。